Ultragenyx Pharmaceutical Future Growth
Future criteria checks 2/6
Ultragenyx Pharmaceutical is forecast to grow earnings and revenue by 50.7% and 30.9% per annum respectively. EPS is expected to grow by 53% per annum. Return on equity is forecast to be -55.3% in 3 years.
Key information
50.7%
Earnings growth rate
53.0%
EPS growth rate
| Biotechs earnings growth | 29.9% |
| Revenue growth rate | 30.9% |
| Future return on equity | -55.3% |
| Analyst coverage | Good |
| Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 848 | -337 | -235 | -321 | 16 |
| 12/31/2025 | 625 | -495 | -293 | -334 | 20 |
| 12/31/2024 | 537 | -553 | -413 | -369 | 19 |
| 6/30/2024 | 481 | -585 | -492 | -469 | N/A |
| 3/31/2024 | 443 | -613 | -544 | -509 | N/A |
| 12/31/2023 | 434 | -607 | -522 | -475 | N/A |
| 9/30/2023 | 410 | -635 | -553 | -481 | N/A |
| 6/30/2023 | 403 | -721 | -553 | -459 | N/A |
| 3/31/2023 | 384 | -719 | -529 | -420 | N/A |
| 12/31/2022 | 363 | -707 | -527 | -380 | N/A |
| 9/30/2022 | 343 | -678 | -480 | -344 | N/A |
| 6/30/2022 | 334 | -506 | -438 | -309 | N/A |
| 3/31/2022 | 332 | -470 | -416 | -297 | N/A |
| 12/31/2021 | 351 | -454 | -412 | -339 | N/A |
| 9/30/2021 | 360 | -356 | -426 | -347 | N/A |
| 6/30/2021 | 359 | -351 | -411 | -349 | N/A |
| 3/31/2021 | 334 | -204 | -243 | -196 | N/A |
| 12/31/2020 | 271 | -187 | -176 | -132 | N/A |
| 9/30/2020 | 215 | -256 | -175 | -142 | N/A |
| 6/30/2020 | 159 | -301 | -203 | -168 | N/A |
| 3/31/2020 | 122 | -425 | -381 | -345 | N/A |
| 12/31/2019 | 104 | -403 | -370 | -345 | N/A |
| 9/30/2019 | 84 | -397 | -344 | -329 | N/A |
| 6/30/2019 | 70 | -371 | -320 | -310 | N/A |
| 3/31/2019 | 59 | -325 | -304 | -297 | N/A |
| 12/31/2018 | 51 | -198 | -295 | -291 | N/A |
| 9/30/2018 | 38 | -192 | -320 | -317 | N/A |
| 6/30/2018 | 26 | -183 | -313 | -309 | N/A |
| 3/31/2018 | 13 | -204 | N/A | -282 | N/A |
| 12/31/2017 | 3 | -302 | N/A | -254 | N/A |
| 9/30/2017 | 0 | -292 | N/A | -220 | N/A |
| 6/30/2017 | 0 | -277 | N/A | -186 | N/A |
| 3/31/2017 | 0 | -261 | N/A | -177 | N/A |
| 12/31/2016 | 0 | -246 | N/A | -161 | N/A |
| 9/30/2016 | 0 | -230 | N/A | -154 | N/A |
| 6/30/2016 | 0 | -204 | N/A | -156 | N/A |
| 3/31/2016 | N/A | -177 | N/A | -133 | N/A |
| 12/31/2015 | N/A | -146 | N/A | -106 | N/A |
| 9/30/2015 | N/A | -107 | N/A | -78 | N/A |
| 6/30/2015 | N/A | -84 | N/A | -58 | N/A |
| 3/31/2015 | N/A | -68 | N/A | -52 | N/A |
| 12/31/2014 | N/A | -65 | N/A | -45 | N/A |
| 9/30/2014 | N/A | -67 | N/A | -42 | N/A |
| 6/30/2014 | N/A | -63 | N/A | -38 | N/A |
| 3/31/2014 | N/A | -61 | N/A | -36 | N/A |
| 12/31/2013 | N/A | -50 | N/A | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RARE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RARE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RARE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RARE's revenue (30.9% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: RARE's revenue (30.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RARE is forecast to be unprofitable in 3 years.